类风湿关节炎患者接受三联治疗的持续率低及与柳氮磺吡啶相关的不良药物事件
该研究基于2006至2012年美国退伍军人事务部临床与管理数据,比较甲氨蝶呤联合肿瘤坏死因子抑制剂(MTX-TNFi)与三联疗法在类风湿关节炎(RA)患者中的持续性和依从性。1年完全持续率MTX-TNFi组为45%(n=2,125),三联疗法组为18%(n=171)(P<0.001);依从率分别为26%和11%(P<0.0001)。三联疗法组治疗中断更多,最常归因于柳氮磺吡啶(SSZ)的不良药物事件。
要点
- 1年完全持续率:MTX-TNFi组45% vs 三联疗法组18%(P<0.001)。
- 依从率(覆盖天数比例≥80%):MTX-TNFi组26% vs 三联疗法组11%(P<0.0001)。
- 三联疗法组治疗中断更多,最常归因于SSZ的不良药物事件。
核心结论
- MTX-TNFi组与三联疗法组在持续性和依从性方面的差异似乎主要与最常归因于SSZ的不良药物事件有关。
研究设计与样本
- 利用2006至2012年退伍军人事务部临床与管理数据,纳入从MTX升级至MTX-TNFi或三联疗法的RA退伍军人,观察联合治疗启动后12个月。
- 持续性定义为治疗无≥90天间隙;依从性采用12个月时覆盖天数比例≥80%计算;应用匹配权重调整模型以更接近模拟随机化;通过病历摘录识别停用联合方案的原因。
主要发现
- 1年完全持续率:MTX-TNFi组45%(n=2,125) vs 三联疗法组18%(n=171)(P<0.001)。
- 依从率:MTX-TNFi组26% vs 三联疗法组11%(P<0.0001)。
- 三联疗法组与显著更多的治疗中断相关,最常归因于SSZ的不良药物事件。
关键数值与推荐
- 持续性:治疗无≥90天间隙。
- 依从性:12个月时覆盖天数比例≥80%。
- 1年完全持续率:MTX-TNFi组45%(n=2,125) vs 三联疗法组18%(n=171)(P<0.001)。
- 依从率:MTX-TNFi组26% vs 三联疗法组11%(P<0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Combination treatments for patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX) alone include the addition of a tumor necrosis factor inhibitor (TNFi) or the addition of sulfasalazine (SSZ) and hydroxychloroquine to MTX (triple therapy). We compared persistence and adherence rates between these 2 combination therapies in US veterans and report the reasons for discontinuation of combination treatment in these groups. METHODS: Using Veteran's Affairs clinical and administrative data from 2006 to 2012, veterans with RA escalating treatment from MTX to MTX-TNFi or triple therapy were examined for a 12-month period after combination initiation. Persistence was defined as treatment without a ≥90-day gap in therapy. Adherence was calculated using the proportion of days covered ≥80% at 12 months. Matching weights-adjusted models were applied to more closely mimic randomization in this study. The reasons that patients discontinued their combination regimens were identified by chart abstraction. RESULTS: Full persistence at 1 year was 45% in the MTX-TNFi patients (n = 2,125) and 18% in the triple therapy patients (n = 171) (P < 0.001). Adherence was higher for the MTX-TNFi group (26%) than the triple therapy group (11%) (P < 0.0001). The triple therapy group was associated with significantly more treatment discontinuation, which was most often due to adverse drug events from SSZ. CONCLUSION: Differences in persistence and adherence between the MTX-TNFi and triple therapy groups appear to be primarily related to adverse drug events that were most often attributed to SSZ.
引用
- Erhardt DP, Cannon GW, Teng CC, et al. Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. Arthritis Care Res (Hoboken). 2019. PMID: 30221485. doi:10.1002/acr.23759
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。